<h2>关键点</h2>
<ul>
<li>强生在最具挑战性的条件下也能表现良好。</li>
<li>公司的信用评级和分红记录强有力地证明了其业务的实力。</li>
<li>尽管面临一些风险，这家制药公司仍然是长期投资的首选。</li>
<li>我们更看好的 10 只股票超过强生 ›</li>
</ul>
<p>我们生活在一个动荡的时代，宏观经济冲突和日益严重的通货膨胀等问题层出不穷。尽管面临这些挑战，股市今年表现良好，但通过投资于能够应对任何环境的强大公司来为市场下跌做好准备始终是个好主意。现在考虑投资的一个顶级股票是 <strong>强生</strong>（NYSE: JNJ），这是一家领先的医疗保健公司。让我们来看看为什么这家制药公司在当前环境中如此吸引人。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-dXJsPWh0dHBzOi8vZy5mb29sY2RuLmNvbS9lZGl0b3JpYWwvaW1hZ2VzLzg2OTc3OS9qb2huc29uLWpvaG5zb24tbG9nby5wbmcWdz03MDA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-dXJsPWh0dHBzOi8vZy5mb29sY2RuLmNvbS9lZGl0b3JpYWwvaW1hZ2VzLzg2OTc3OS9qb2huc29uLWpvaG5zb24tbG9nby5wbmcWdz03MDA"/></p>
<p>图片来源：The Motley Fool。</p>
<p><em><strong>人工智能会创造出世界上第一个万亿富翁吗？</strong> 我们的团队刚刚发布了一份报告，介绍了一家鲜为人知的公司，被称为 “不可或缺的垄断”，提供 Nvidia 和 Intel 都需要的关键技术。<strong>继续 »</strong></em></p>
<h2>它能抵御每一次风暴</h2>
<p>强生的多个业务方面使其成为在市场崩溃、经济衰退或两者兼而有之时值得拥有的优秀股票。我们来考虑其中的三个方面。首先，强生销售人们在任何经济条件下都依赖的必需品，包括药品和医疗设备。当形势变得艰难时，没有人愿意停止服用救命药物。而且，由于第三方支付者帮助承担了患者的大部分费用，许多人在经济紧缩时仍然能够负担得起药物。强生帮助医生使用其设备进行的手术需求在经济周期中也往往保持高位。</p>
<p>至关重要的是，强生远不止是一家能够抵御经济衰退的典型医疗公司，因为其产品始终保持高需求。它是该行业中多元化程度较高的参与者之一。该制药公司的药品组合涵盖多个类别。其医疗技术部门也是如此。强生还有一个深厚的产品管道，使其能够定期获得全新的批准或标签扩展。其次，强生拥有坚如磐石的资产负债表。</p>
<p>或许最有力的证据之一是该公司获得的 S&amp;P Global AAA 信用评级。这不仅高于美国政府的评级，而且是最高的评级。因此，无论危机如何，强生更有可能履行其义务。第三，强生是一个分红之王。这些公司连续 50 次（或更多）提高分红——强生的连续记录达到了 64 次。这再次突显了其基础业务的实力，因为持续支付分红，尤其是每年提高分红，并非易事。定期的分红也可以帮助在经济衰退期间减轻市场损失。</p>
<h2>强生能够克服其挑战</h2>
<p>尽管强生的业务稳健，但投资者应注意至少两个风险。其中一个风险已经困扰该公司很长时间。强生仍在处理成千上万的诉讼，原告声称其含滑石粉的产品导致他们患癌症。这家制药巨头尝试了多种策略来将大部分诉讼抛在脑后，但迄今为止未能成功。其次，美国政府的价格谈判对强生的财务结果可能产生影响。</p>
<p>监管机构已经针对该公司的几种产品进行了谈判。如果未来再选择更多产品，这可能会成为一个严重的阻力。尽管面临这些问题，强生的股票仍然具有吸引力。公司的法律问题并没有改变其信用评级，这强烈表明这些诉讼不会使其财务崩溃。即使未来有巨额赔偿，强生也应该能够应对。至于政府价格谈判，尽管如此，强生目前的表现仍然良好。尽管政府谈判的三种产品的价格在今年生效，但该公司预计到 2026 年销售额将同比增长约 7%（中位数）至 1008 亿美元。</p>
<p>强生已经存在超过 100 年。在其辉煌的历史中，它经历了美国医疗保健行业的巨大变化，包括医疗保险和医疗补助的引入等。过去并不能保证未来，但公司的优势——如其庞大、多元化的产品组合和管道以及创新能力——使其能够在过去克服类似挑战，并且可以再次做到。因此，投资者应保持持有。强生能够在这一环境中航行，并在长期内提供稳健的回报，尤其是对于那些将分红再投资的投资者。</p>
<h2>你现在应该购买强生的股票吗？</h2>
<p>在你购买强生的股票之前，请考虑以下几点：</p>
<p><em>Motley Fool Stock Advisor</em> 分析师团队刚刚确定了他们认为的 <strong>10 只最佳股票</strong> 供投资者现在购买……而强生并不在其中。入选的 10 只股票在未来几年可能会产生巨额回报。</p>
<p>考虑一下 <strong>Netflix</strong> 在 2004 年 12 月 17 日上榜时……如果你在我们推荐时投资了 1000 美元，<strong>你将拥有 469,293 美元</strong>！* 或者当 <strong>Nvidia</strong> 在 2005 年 4 月 15 日上榜时……如果你在我们推荐时投资了 1000 美元，<strong>你将拥有 1,381,332 美元</strong>！*</p>
<p>现在值得注意的是，<em>Stock Advisor</em> 的总平均回报率为 993% — 远超标普 500 的 207%。<strong>不要错过最新的前 10 名股票列表，使用 <em>Stock Advisor</em>，加入由个人投资者为个人投资者建立的投资社区。</strong></p>
<p><strong>查看这 10 只股票 »</strong></p>
<p><em>*Stock Advisor 的回报截至 2026 年 5 月 19 日。</em></p>
<p><em>Prosper Junior Bakiny 持有强生的股份。Motley Fool 推荐强生。Motley Fool 有披露政策。</em></p>
<p>此处表达的观点和意见仅代表作者的观点和意见，并不一定反映纳斯达克公司的观点。</p>

强生

医疗业 ETF - SPDR

美国制药 ETF - iShares

标普健康医疗设备 ETF - SPDR

标普全球医疗股指数 ETF - iShares

医疗业 ETF - Vanguard

美国医药设备 ETF - iShares

<p>强生（Johnson & Johnson，NYSE: JNJ）被认为是一个强劲的投资选择，原因在于其稳健的商业模式、AAA 的信用评级以及连续 64 年的分红增长历史。尽管面临法律挑战和潜在的政府价格谈判，该公司预计到 2026 年销售额将同比增长 7%。其多元化的产品组合和必需品使其在经济低迷时期能够良好应对，成为寻求稳定的投资者的可靠选择</p>

<h2>Key Points</h2>
<div class="lb-trans"><h2>关键点</h2>
</div><ul>
<li>Johnson &amp; Johnson's business can perform well under the most challenging conditions.</li>
<li>The company's credit rating and dividend track record provide strong evidence of the business's strength.</li>
<li>While there are some risks it faces, the drugmaker remains a top long-term pick.</li>
<li>10 stocks we like better than Johnson &amp; Johnson ›</li>
</ul>
<div class="lb-trans"><ul>
<li>强生在最具挑战性的条件下也能表现良好。</li>
<li>公司的信用评级和分红记录强有力地证明了其业务的实力。</li>
<li>尽管面临一些风险，这家制药公司仍然是长期投资的首选。</li>
<li>我们更看好的 10 只股票超过强生 ›</li>
</ul>
</div><p>We live in pretty volatile times marked by macroeconomic conflicts and worsening inflation, among other things. Equity markets have fared well this year despite these challenges, but it's always a good idea to prepare for market downturns by investing in robust companies that can navigate any environment. One top stock to consider investing in right now to stabilize a well-diversified portfolio is <strong>Johnson &amp; Johnson</strong>(NYSE: JNJ), a leading healthcare player. Let's get into why the drugmaker is such an attractive pick in the current landscape.</p>
<div class="lb-trans"><p>我们生活在一个动荡的时代，宏观经济冲突和日益严重的通货膨胀等问题层出不穷。尽管面临这些挑战，股市今年表现良好，但通过投资于能够应对任何环境的强大公司来为市场下跌做好准备始终是个好主意。现在考虑投资的一个顶级股票是 <strong>强生</strong>（NYSE: JNJ），这是一家领先的医疗保健公司。让我们来看看为什么这家制药公司在当前环境中如此吸引人。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-dXJsPWh0dHBzOi8vZy5mb29sY2RuLmNvbS9lZGl0b3JpYWwvaW1hZ2VzLzg2OTc3OS9qb2huc29uLWpvaG5zb24tbG9nby5wbmcmdz03MDA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F869779%2Fjohnson-johnson-logo.png&amp;w=700"/></p>
<p>Image source: The Motley Fool.</p>
<div class="lb-trans"><p>图片来源：The Motley Fool。</p>
</div><p><em><strong>Will AI create the world's first trillionaire?</strong> Our team just released a report on the one little-known company, called an &#34;Indispensable Monopoly&#34; providing the critical technology Nvidia and Intel both need. <strong>Continue »</strong></em></p>
<div class="lb-trans"><p><em><strong>人工智能会创造出世界上第一个万亿富翁吗？</strong> 我们的团队刚刚发布了一份报告，介绍了一家鲜为人知的公司，被称为 “不可或缺的垄断”，提供 Nvidia 和 Intel 都需要的关键技术。<strong>继续 »</strong></em></p>
</div><h2>It can weather every storm</h2>
<div class="lb-trans"><h2>它能抵御每一次风暴</h2>
</div><p>Several aspects of Johnson &amp; Johnson's business make it an outstanding stock to own during a market crash, an economic downturn, or both. Let's consider three of them. First, Johnson &amp; Johnson sells essential products that people depend on regardless of economic conditions, including pharmaceutical drugs and medical devices. No one wants to stop taking lifesaving medicines when the going gets rough. And because third-party payers help foot much of the bill for patients, many can still afford to take their meds when the purse strings tighten. Demand for the procedures that Johnson &amp; Johnson helps physicians perform with its devices also tends to remain high across the economic cycle.</p>
<div class="lb-trans"><p>强生的多个业务方面使其成为在市场崩溃、经济衰退或两者兼而有之时值得拥有的优秀股票。我们来考虑其中的三个方面。首先，强生销售人们在任何经济条件下都依赖的必需品，包括药品和医疗设备。当形势变得艰难时，没有人愿意停止服用救命药物。而且，由于第三方支付者帮助承担了患者的大部分费用，许多人在经济紧缩时仍然能够负担得起药物。强生帮助医生使用其设备进行的手术需求在经济周期中也往往保持高位。</p>
</div><p>Crucially, Johnson &amp; Johnson is far more than a typical healthcare company that can withstand downturns because its products remain in high demand. It is one of the more diversified players in the sector. The drugmaker's pharmaceutical portfolio spans several categories. We can say the same about its medtech division. And Johnson &amp; Johnson also has a deep pipeline that allows it to score regular brand-new approvals or label expansions. Second, Johnson &amp; Johnson has a rock-solid balance sheet.</p>
<div class="lb-trans"><p>至关重要的是，强生远不止是一家能够抵御经济衰退的典型医疗公司，因为其产品始终保持高需求。它是该行业中多元化程度较高的参与者之一。该制药公司的药品组合涵盖多个类别。其医疗技术部门也是如此。强生还有一个深厚的产品管道，使其能够定期获得全新的批准或标签扩展。其次，强生拥有坚如磐石的资产负债表。</p>
</div><p>Perhaps one of the best pieces of evidence for that is the company's AAA credit rating from S&amp;P Global. Not only is it higher than that of the U.S. Government, but it is also the highest available. So, no matter the crisis, it's more than likely that Johnson &amp; Johnson will be able to take care of its obligations. Third, Johnson &amp; Johnson is a Dividend King. Those are companies with 50 (or more) straight payout increases -- Johnson &amp; Johnson's streak is at 64. This once again highlights the strength of its underlying business, as paying dividends for that long, let alone raising them every year, is no easy feat. The regular payouts can also help mitigate market losses during a downturn.</p>
<div class="lb-trans"><p>或许最有力的证据之一是该公司获得的 S&amp;P Global AAA 信用评级。这不仅高于美国政府的评级，而且是最高的评级。因此，无论危机如何，强生更有可能履行其义务。第三，强生是一个分红之王。这些公司连续 50 次（或更多）提高分红——强生的连续记录达到了 64 次。这再次突显了其基础业务的实力，因为持续支付分红，尤其是每年提高分红，并非易事。定期的分红也可以帮助在经济衰退期间减轻市场损失。</p>
</div><h2>Johnson &amp; Johnson can overcome its challenges</h2>
<div class="lb-trans"><h2>强生能够克服其挑战</h2>
</div><p>Even though Johnson &amp; Johnson has a solid business, there are at least two risks investors should keep in mind. One of them has been hanging over the company's head for a long time. Johnson &amp; Johnson is still dealing with thousands of lawsuits from plaintiffs who claim that its talc-based products gave them cancer. The pharmaceutical leader has tried several tactics to put most of these in the rearview mirror. So far, it has failed. Then, there is the potential impact of government price negotiations in the U.S. on Johnson &amp; Johnson's financial results.</p>
<div class="lb-trans"><p>尽管强生的业务稳健，但投资者应注意至少两个风险。其中一个风险已经困扰该公司很长时间。强生仍在处理成千上万的诉讼，原告声称其含滑石粉的产品导致他们患癌症。这家制药巨头尝试了多种策略来将大部分诉讼抛在脑后，但迄今为止未能成功。其次，美国政府的价格谈判对强生的财务结果可能产生影响。</p>
</div><p>Regulators have already targeted several of the company's products for negotiation. If they pick even more in the future, it could become a serious headwind. Even with these problems, though, Johnson &amp; Johnson's shares are attractive. The company's legal issues haven't changed its credit rating, which strongly suggests these lawsuits won't financially ruin it. Even if there is a massive payout in the future, Johnson &amp; Johnson should be able to handle it. Regarding government price negotiations, Johnson &amp; Johnson is performing well so far despite that. The company is expecting its sales to grow by about 7% year over year (at the midpoint) in 2026 to $100.8 billion, even though government-negotiated prices for three of its products kicked in this year.</p>
<div class="lb-trans"><p>监管机构已经针对该公司的几种产品进行了谈判。如果未来再选择更多产品，这可能会成为一个严重的阻力。尽管面临这些问题，强生的股票仍然具有吸引力。公司的法律问题并没有改变其信用评级，这强烈表明这些诉讼不会使其财务崩溃。即使未来有巨额赔偿，强生也应该能够应对。至于政府价格谈判，尽管如此，强生目前的表现仍然良好。尽管政府谈判的三种产品的价格在今年生效，但该公司预计到 2026 年销售额将同比增长约 7%（中位数）至 1008 亿美元。</p>
</div><p>Johnson &amp; Johnson has been around for over 100 years. Throughout its storied history, it has dealt with massive changes to the healthcare sector in the U.S., including the introduction of Medicare and Medicaid, and many others. The past is no guarantee of the future, but the company's strengths -- such as its vast, diversified portfolio and pipeline and innovative capabilities -- have allowed it to overcome similar challenges in the past and can do so again. So, investors should stay put. Johnson &amp; Johnson can navigate this landscape and deliver solid returns over the long run, especially for investors who reinvest the dividend.</p>
<div class="lb-trans"><p>强生已经存在超过 100 年。在其辉煌的历史中，它经历了美国医疗保健行业的巨大变化，包括医疗保险和医疗补助的引入等。过去并不能保证未来，但公司的优势——如其庞大、多元化的产品组合和管道以及创新能力——使其能够在过去克服类似挑战，并且可以再次做到。因此，投资者应保持持有。强生能够在这一环境中航行，并在长期内提供稳健的回报，尤其是对于那些将分红再投资的投资者。</p>
</div><h2>Should you buy stock in Johnson &amp; Johnson right now?</h2>
<div class="lb-trans"><h2>你现在应该购买强生的股票吗？</h2>
</div><p>Before you buy stock in Johnson &amp; Johnson, consider this:</p>
<div class="lb-trans"><p>在你购买强生的股票之前，请考虑以下几点：</p>
</div><p>The <em>Motley Fool Stock Advisor</em> analyst team just identified what they believe are the <strong>10 best stocks</strong> for investors to buy now… and Johnson &amp; Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.</p>
<div class="lb-trans"><p><em>Motley Fool Stock Advisor</em> 分析师团队刚刚确定了他们认为的 <strong>10 只最佳股票</strong> 供投资者现在购买……而强生并不在其中。入选的 10 只股票在未来几年可能会产生巨额回报。</p>
</div><p>Consider when <strong>Netflix</strong> made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, <strong>you’d have $469,293</strong>!* Or when <strong>Nvidia</strong> made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, <strong>you’d have $1,381,332</strong>!*</p>
<div class="lb-trans"><p>考虑一下 <strong>Netflix</strong> 在 2004 年 12 月 17 日上榜时……如果你在我们推荐时投资了 1000 美元，<strong>你将拥有 469,293 美元</strong>！* 或者当 <strong>Nvidia</strong> 在 2005 年 4 月 15 日上榜时……如果你在我们推荐时投资了 1000 美元，<strong>你将拥有 1,381,332 美元</strong>！*</p>
</div><p>Now, it’s worth noting <em>Stock Advisor’s</em> total average return is 993% — a market-crushing outperformance compared to 207% for the S&amp;P 500. <strong>Don't miss the latest top 10 list, available with <em>Stock Advisor</em>, and join an investing community built by individual investors for individual investors.</strong></p>
<div class="lb-trans"><p>现在值得注意的是，<em>Stock Advisor</em> 的总平均回报率为 993% — 远超标普 500 的 207%。<strong>不要错过最新的前 10 名股票列表，使用 <em>Stock Advisor</em>，加入由个人投资者为个人投资者建立的投资社区。</strong></p>
</div><p><strong>See the 10 stocks »</strong></p>
<div class="lb-trans"><p><strong>查看这 10 只股票 »</strong></p>
</div><p><em>*Stock Advisor returns as of May 19, 2026.</em></p>
<div class="lb-trans"><p><em>*Stock Advisor 的回报截至 2026 年 5 月 19 日。</em></p>
</div><p><em>Prosper Junior Bakiny has positions in Johnson &amp; Johnson. The Motley Fool recommends Johnson &amp; Johnson. The Motley Fool has a disclosure policy.</em></p>
<div class="lb-trans"><p><em>Prosper Junior Bakiny 持有强生的股份。Motley Fool 推荐强生。Motley Fool 有披露政策。</em></p>
</div><p>The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.</p>
<div class="lb-trans"><p>此处表达的观点和意见仅代表作者的观点和意见，并不一定反映纳斯达克公司的观点。</p>
</div>

与信用评级高于美国政府的股息之王会面